Late-onset Unexplained Epilepsy as a Risk Factor for Dementia
迟发性不明原因癫痫是痴呆症的危险因素
基本信息
- 批准号:10739517
- 负责人:
- 金额:$ 295.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2028-05-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAffectAgeAlzheimer&aposs disease pathologyAlzheimer&aposs disease related dementiaAlzheimer&aposs disease riskAmyloidBig DataBiological MarkersBiometryBlood VesselsBrainCerebrovascular DisordersClinicalClinical TrialsCognitiveDataData SetDementiaDevelopmentElderlyElectroencephalographyEnrollmentEpilepsyEvaluationFamilyFoundationsFutureGoalsImpaired cognitionIncidenceIndividualKnowledgeLearningLongitudinal, observational studyMachine LearningMagnetic Resonance ImagingMeasurementModelingNeurodegenerative DisordersNeuropsychologyOutcomeParticipantPathologyPatientsPatternPharmaceutical PreparationsPhenotypePlasmaPopulationPreventionPrognosisRecording of previous eventsResearchRiskRisk AssessmentRisk FactorsRisk ReductionSeizuresSeveritiesSiteTestingTherapeuticThickWorkbrain magnetic resonance imagingclinical careclinical phenotypeclinical riskcognitive testingcomorbiditydementia riskdemographicsdesigndisorder subtypeepileptiformhigh riskimprovedinsightinterestlifestyle factorsmachine learning methodmixed dementianeural networkneuroimagingneuropathologyneurophysiologynoveloutcome predictionprecision medicinepreventprognosticationprospectiverisk stratificationsleep physiologytargeted treatmenttau Proteinstherapeutic developmenttoolunsupervised learning
项目摘要
Project Summary / Abstract
Late-onset unexplained epilepsy (LoUE), defined as epilepsy starting after age 55 with no clearly identified
cause, has emerged as a significant risk factor for Alzheimer’s disease and related dementias (AD/ADRD). LoUE
afflicts 50,000 new patients in the U.S. each year and will soon affect many more as our elderly population grows.
Individuals presenting with LoUE have no prior history of dementia. Yet, LoUE is associated with a 2-3x increased
risk of developing dementia, and up to 25% of LoUE develop dementia within 4 years after their first seizure. We
have little understanding of the mechanisms underlying dementia in LoUE; no tools to predict which individuals
with LoUE are at highest risk; and no treatments to prevent dementia in LoUE. 30-40% of LoUE may harbor AD
pathology and/or occult cerebrovascular disease, and we hypothesize that these pathologies drive much of the
increased dementia risk in LoUE. Yet, other pathologies and mechanisms are also possible and need to be
identified. Our long-term goal is to develop a precision medicine approach to preventing dementia in LoUE, in
which individualized risk assessment and disease subtyping can specifically inform a patient’s dementia
prognosis and guide targeted therapies to reduce dementia risk. We hypothesize that rigorous, data-driven
phenotyping of LoUE based on clinical features, biomarkers, and cognitive outcomes, will advance mechanistic
understanding of dementia in LoUE and accelerate therapeutic development to reduce dementia risk. The goals
of this proposal are to elucidate the risk factors and mechanisms that lead to dementia in LoUE and to develop
tools for dementia risk-stratification in LoUE. To accomplish these goals, we will carry out a prospective, multi-
center, longitudinal observational study of LoUE focused on understanding mechanisms and predicting
outcomes of AD/ADRD in LoUE. We will enroll 600 participants with LoUE across 7 sites over 3 years.
Participants will undergo a baseline evaluation with clinical history, cognitive testing, brain MRI, overnight EEG,
and plasma AD biomarkers, and will be followed longitudinally with interval history every 6 months and annual
cognitive testing. Our specific aims are: 1) To establish an unbiased framework for identifying mechanisms
leading to dementia in LoUE, we will organize LoUE into disease subtypes based on: (a) associated
neuropathology; (b) clinical phenotype; and (c) cognitive trajectory; 2) To advance mechanistic understanding of
dementia in LoUE, we will identify epilepsy-related, neuropathologic, neurophysiologic, and structural features
associated with development of dementia in LoUE; and 3) To enable prognostication of dementia in LoUE, we
will develop practical clinical tools to forecast an individual’s risk of developing dementia after presentation with
LoUE. This study will be the first large-scale study of LoUE that will define its relationship to AD/ADRD and have
sufficient power to draw conclusions that will directly impact clinical care. This study will also establish
foundational knowledge and risk-stratification tools that will facilitate the design of efficient and informative clinical
trials for dementia prevention in LoUE.
项目总结/摘要
迟发性不明原因癫痫(Late onset unexplained epilepsy,LoUE),定义为55岁以后开始的癫痫,
阿尔茨海默氏病和相关痴呆症(AD/ADRD)的一个重要危险因素。loue
在美国,每年有5万名新患者受到影响,随着老年人口的增长,很快还会有更多的患者受到影响。
患有LoUE的人没有痴呆症的既往史。然而,LoUE与2 - 3倍的增加相关,
有发生痴呆的风险,高达25%的LoUE在首次癫痫发作后4年内发生痴呆。我们
对LoUE中痴呆的潜在机制知之甚少;没有工具来预测哪些个体
LoUE患者的风险最高;并且没有治疗方法来预防LoUE中的痴呆症。30 - 40%的LoUE可能携带AD
病理学和/或隐匿性脑血管疾病,我们假设这些病理学驱动了大部分的
LOUE中痴呆风险增加。然而,其他病理和机制也是可能的,并且需要考虑。
鉴定我们的长期目标是开发一种精确的医学方法来预防LoUE中的痴呆症,
哪种个性化的风险评估和疾病亚型可以明确地告知患者的痴呆症
预测和指导靶向治疗以降低痴呆风险。我们假设严格的数据驱动的
基于临床特征、生物标志物和认知结果的LoUE表型分型,将促进
了解LoUE中的痴呆症,并加速治疗开发以降低痴呆症风险。的目标
这项建议的目的是阐明导致LoUE痴呆的危险因素和机制,
LoUE中痴呆风险分层的工具。为了实现这些目标,我们将开展一项前瞻性的、多方面的工作,
中心,LoUE的纵向观察性研究,重点是了解机制和预测
LoUE中AD/ADRD的结局。我们将在3年内在7个研究中心招募600名LoUE受试者。
参与者将接受基线评估,包括临床病史、认知测试、脑MRI、夜间EEG,
和血浆AD生物标志物,并将每6个月和每年对间隔史进行纵向随访
认知测试我们的具体目标是:1)建立一个公正的框架,以确定机制
导致LoUE中的痴呆,我们将根据以下因素将LoUE组织成疾病亚型:(a)相关
神经病理学;(B)临床表型;和(c)认知轨迹; 2)促进对
在LoUE痴呆中,我们将识别癫痫相关的神经病理学、神经生理学和结构特征
与LoUE中痴呆的发展相关;和3)为了使LoUE中痴呆的诊断成为可能,我们
将开发实用的临床工具来预测一个人患痴呆症的风险,
LoUE。这项研究将是第一项大规模的LoUE研究,将确定其与AD/ADRD的关系,
有足够的能力得出直接影响临床护理的结论。这项研究还将建立
基础知识和风险分层工具,这将有助于设计有效和信息丰富的临床
在LoUE中进行痴呆症预防试验。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alice D Lam其他文献
Alice D Lam的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alice D Lam', 18)}}的其他基金
Investigation of silent mesial temporal lobe hyperexcitability in Alzheimer's disease
阿尔茨海默病患者沉默内侧颞叶过度兴奋性的研究
- 批准号:
9977778 - 财政年份:2019
- 资助金额:
$ 295.95万 - 项目类别:
Investigation of silent mesial temporal lobe hyperexcitability in Alzheimer's disease
阿尔茨海默病患者沉默内侧颞叶过度兴奋性的研究
- 批准号:
9808415 - 财政年份:2019
- 资助金额:
$ 295.95万 - 项目类别:
Exploring the role of epileptiform activity in Alzheimer's Disease
探索癫痫样活动在阿尔茨海默病中的作用
- 批准号:
10357868 - 财政年份:2018
- 资助金额:
$ 295.95万 - 项目类别:
Exploring the role of epileptiform activity in Alzheimer's Disease
探索癫痫样活动在阿尔茨海默病中的作用
- 批准号:
9897545 - 财政年份:2018
- 资助金额:
$ 295.95万 - 项目类别:
Exploring the role of epileptiform activity in Alzheimer's Disease
探索癫痫样活动在阿尔茨海默病中的作用
- 批准号:
9526093 - 财政年份:2018
- 资助金额:
$ 295.95万 - 项目类别:
Defining the Role of Lipid Rafts in Neurotransmission
定义脂筏在神经传递中的作用
- 批准号:
7107251 - 财政年份:2005
- 资助金额:
$ 295.95万 - 项目类别:
Defining the Role of Lipid Rafts in Neurotransmission
定义脂筏在神经传递中的作用
- 批准号:
6998225 - 财政年份:2005
- 资助金额:
$ 295.95万 - 项目类别:
Defining the Role of Lipid Rafts in Neurotransmission
定义脂筏在神经传递中的作用
- 批准号:
7442172 - 财政年份:2005
- 资助金额:
$ 295.95万 - 项目类别:
相似海外基金
Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
- 批准号:
495182 - 财政年份:2023
- 资助金额:
$ 295.95万 - 项目类别:
Investigating how alternative splicing processes affect cartilage biology from development to old age
研究选择性剪接过程如何影响从发育到老年的软骨生物学
- 批准号:
2601817 - 财政年份:2021
- 资助金额:
$ 295.95万 - 项目类别:
Studentship
RAPID: Coronavirus Risk Communication: How Age and Communication Format Affect Risk Perception and Behaviors
RAPID:冠状病毒风险沟通:年龄和沟通方式如何影响风险认知和行为
- 批准号:
2029039 - 财政年份:2020
- 资助金额:
$ 295.95万 - 项目类别:
Standard Grant
Neighborhood and Parent Variables Affect Low-Income Preschool Age Child Physical Activity
社区和家长变量影响低收入学龄前儿童的身体活动
- 批准号:
9888417 - 财政年份:2019
- 资助金额:
$ 295.95万 - 项目类别:
The affect of Age related hearing loss for cognitive function
年龄相关性听力损失对认知功能的影响
- 批准号:
17K11318 - 财政年份:2017
- 资助金额:
$ 295.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9320090 - 财政年份:2017
- 资助金额:
$ 295.95万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
10166936 - 财政年份:2017
- 资助金额:
$ 295.95万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9761593 - 财政年份:2017
- 资助金额:
$ 295.95万 - 项目类别:
How age dependent molecular changes in T follicular helper cells affect their function
滤泡辅助 T 细胞的年龄依赖性分子变化如何影响其功能
- 批准号:
BB/M50306X/1 - 财政年份:2014
- 资助金额:
$ 295.95万 - 项目类别:
Training Grant
Inflamm-aging: What do we know about the effect of inflammation on HIV treatment and disease as we age, and how does this affect our search for a Cure?
炎症衰老:随着年龄的增长,我们对炎症对艾滋病毒治疗和疾病的影响了解多少?这对我们寻找治愈方法有何影响?
- 批准号:
288272 - 财政年份:2013
- 资助金额:
$ 295.95万 - 项目类别:
Miscellaneous Programs